**AzNETT NEWSLETTER**

**Mission:** The mission of the Neurologic Emergencies Treatment Trials (NETT) Network is to improve outcomes of patients with acute neurologic problems through innovative research focused on the emergent phase of patient care.

**Vision:** NETT will engage clinicians and providers at the front lines of emergency care to conduct large, simple multicenter clinical trials to answer research questions of clinical importance. The NETT structure will be utilized to achieve economies of scale enabling cost effective, high quality research.
Please welcome our new full time Research Specialist, Lisa Slayton, LPN. Lisa has a background in critical care and has experience working critical care clinical trials. Outside work, Lisa enjoys ballet, gardening, house renovations with her husband Rick, and swimming with her yellow lab, Bailey.

Courage is grace under pressure ~ Ernest Hemingway

CLINICAL TRIALS

ALIAS - Albumin in Acute Stroke Trial

Local PI: Bruce Coull, MD

NETT PI: Myron Ginsberg, MD - University of Miami

Primary Objective: To determine whether albumin therapy increases the proportion of acute ischemic stroke patients with favorable outcome compared to placebo therapy at 3 months from randomization.

Status: 100 patients screened with 4 enrolled. Nationwide, there are 298 patients enrolled.
RAMPART - Rapid Anticonvulsant Medication Prior to Arrival Trial

Local PI: Dan Spaite, MD, Ben Bobrow, MD and Garth Gemar, MD

NETT PI: Robert Silbergleit, MD - University of Michigan

Primary Objective: To determine if the efficacy of intramuscular (IM) midazolam is not inferior to intravenous (IV) lorazepam by a pre-specified clinically unimportant absolute difference in the prehospital treatment of status epilepticus.

Status: 48 patients enrolled locally. Nationally 600 patients enrolled.

ProTECT - Progesterone for Traumatic Brain Injury: Experimental Clinical Treatment

Local PI: Randy Friese, MD

NETT PI: David Wright, MD - Emory University

Primary Objective: To determine the effectiveness of intravenous progesterone initiated within 4 hours of injury and administered for 96 hours as compared to placebo at improving functional outcome in patients with moderate to severe traumatic brain injury.

Status: Open to enrollment; 40 patients screened, no enrollments. Six patients enrolled nationally.
Please direct any questions you have regarding AzNETT to:

**Principal Investigator, Tucson:** Kurt Denninghoff, MD  
kdenninghoff@aemrc.arizona.edu, phone 520-626-1551

**Research Nurse Coordinator, Tucson:** Ginny Rizzo, RN, CCRC  
rizzo@aemrc.arizona.edu, phone 520-626-5250

**Research Specialist, Tucson:** Lisa Slayton, LPN  
lslayton@aemrc.arizona.edu, phone 520-626-0645

**Research Nurse Coordinator, Phoenix:** Bruce Bamhart, RN, CEP  
bbamhart@aemrc.arizona.edu, phone 602-827-2140

**EMS Coordinator, Phoenix:** Willie Haro, CEP  
gharo@aemrc.arizona.edu, phone 602-827-2140.

**AEMRC Administrative Assistant:** Ronnie Benke  
rbenke@aemrc.arizona.edu, phone 520-626-8819.

*We look forward to working with you!*